Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Blood (2021) 137 (14): 1970–1979.

https://doi.org/10.1182/blood.2020009050

Published: 2021

Includes: Supplemental data

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, David Gottlieb, MBBS, MD FRACP, FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Stephen R Larsen, MBBS PhDFRACP FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Simon Durrant, MBBS FRCP FRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Cameron Curley, MBBS, FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139057

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Stephen R Larsen, MBBS PhDFRACP FRCPA, Andrew Spencer, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Simon Durrant, MBBS FRCP FRCPath, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Hugh J. Goodman, FRACP, Ian H. Kerridge, FRACP FRCPA MPhil BA, Christopher Arthur, Cameron Curley, MBBS, FRACP, FRCPA, Caroline Stewart, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Jennifer Collins, Julian Cooney, FRACP,FRCPA,MBBS,, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139076

Published: 2020

Journal Articles

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Glen A Kennedy, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS,PhDFRACP,FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashish Misra, MBBS, FRACP, Elango Subramoniapillai, MBBS, FRACP, James Morton, MBBS, FRACP, FRCPA, Simon Durrant, FRCP,FRCPath,MBBS, Andrea S Hendon, MBBS, PhD FRACP, FRCPA, John Moore, MDFRACP,FRCPA, David Ritchie, MD PhD, David Gottlieb, MBBS, MD FRACP, FRCPA, Julian Cooney, FRACP,FRCPA,MBBS,, Luke Buizen, BSc (Hons), MSc, Sanjoy K Paul, PhD, Geoff R. Hill, MD

Blood (2019) 134 (Supplement_1): 368.

https://doi.org/10.1182/blood-2019-126285

Published: 2019

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3181.

https://doi.org/10.1182/blood.V124.21.3181.3181

Published: 2014

Journal Articles

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Ronan T Swords, MD PhD FRCPI, FRCPath, Andrew H Wei, MBBS, PhD, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPat, Anjali S. Advani, MD, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Ian D Lewis, MBBS, PhD, Peter L. Greenberg, MD PhD, Jorge E. Cortes, MD, Geoff T Yarranton, PhD, Jackie M. Walling, MBChB, PhD, Jeffrey E. Lancet, MD

Blood (2014) 124 (21): 3756.

https://doi.org/10.1182/blood.V124.21.3756.3756

Published: 2014

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Simon Durrant, MD, Maya Koren-Michowitz, MD, David Lavie, Joaquin Martinez-Lopez, MD PhD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Dana Iommazzo, Prashanth Gopalakrishna, MBBS, MRCS, Heinz Gisslinger, MD

Blood (2014) 124 (21): 710.

https://doi.org/10.1182/blood.V124.21.710.710

Published: 2014

Journal Articles

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H. Brümmendorf, Kimmo Porkka, Giovanni Martinelli, Simon Durrant, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Carlo Gambacorti-Passerini

Blood (2014) 123 (9): 1309–1318.

https://doi.org/10.1182/blood-2013-07-513937

Published: 2014

Includes: Supplemental data

Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4071.

https://doi.org/10.1182/blood.V122.21.4071.4071

Published: 2013

Journal Articles

Results of a Prospective Phase II Randomized Study of Deferasirox (Exjade®) to Prevent Iatrogenic Iron Overload in Patients Undertaking Induction/Consolidation Chemotherapy for Acute Myeloid Leukaemia (HREC/10/QRBW/135)

Glen A Kennedy, MBBS FRACP FRCPA, Kirk Morris, MBBS FRACP FRCPA, Elango Pillai, MBBS FRACP FRCPA, Cameron Curley, MBBS FRACP FRCPA, Jason P. Butler, MBBS, FRACP, FRCPA, MMSc, Simon Durrant

Blood (2012) 120 (21): 3577.

https://doi.org/10.1182/blood.V120.21.3577.3577

Published: 2012

Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Anna G Turkina, Zhi-Xiang Shen, H. Jean Khoury, Tim H Brümmendorf, Philippe Schafhausen, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Tamas Masszi, Simon Durrant, Kimmo Porkka, MD, PhD, Eric Leip, Virginia Kelly, Nadine Besson, Carlo Gambacorti-Passerini

Blood (2012) 120 (21): 3779.

https://doi.org/10.1182/blood.V120.21.3779.3779

Published: 2012

Journal Articles

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Hagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H Brümmendorf, Kimmo Porkka, MD, PhD, Giovanni Martinelli, MD, Simon Durrant, Eric Leip, Nadine Besson, Virginia Kelly, Carlo Gambacorti-Passerini, MD

Blood (2011) 118 (21): 2760.

https://doi.org/10.1182/blood.V118.21.2760.2760

Published: 2011

Journal Articles

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

David S. Siegel, MD, PhD, Meletios Athanasios Dimopoulos, MD, Sung-Soo Yoon, MD, PhD, Jacob P. Laubach, MD, Jonathan L. Kaufman, MD, Hartmut Goldschmidt, MD, Donna E. Reece, MD, FRCPC, Xavier Leleu, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Fritz C. Offner, MD, PhD, Michele Cavo, MD, Arnon Nagler, MD, Sundar Jagannath, MD, Thorsten Graef, MD, PhD, Jennifer Houp, Linda Sun, PhD, Jason Howe, Sandra M. Wear, RN, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 480.

https://doi.org/10.1182/blood.V118.21.480.480

Published: 2011

Journal Articles

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Taimur Sher, MD, Jose Azar, MD, Stephen Spurgeon, MD, John Catalano, MBBS, FRACP, FRCPA, Richard R. Furman, MD, Miles Prince, MD, FRACP, FRCPA, Nancy L. Bartlett, MD, Simon Durrant, MBBS, FRCP, FRCPath, Ralph Boccia, MD, Aisha Masood, MD, Scott Lyman, MS, Jean Cantey-Kiser, William P Sheridan, MB, BS, Asher Chanan-Khan, MD

Blood (2010) 116 (21): 1397.

https://doi.org/10.1182/blood.V116.21.1397.1397

Published: 2010

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

NARROW

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Results of a Prospective Phase II Randomized Study of Deferasirox (Exjade®) to Prevent Iatrogenic Iron Overload in Patients Undertaking Induction/Consolidation Chemotherapy for Acute Myeloid Leukaemia (HREC/10/QRBW/135)

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only